Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 1/20 | 0.48 |
| ▸ | BTK | Q06187 | 2/20 | 0.48 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.47 |
| ▸ | KDR | P35968 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 4/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 10/20 | 0.46 |
| ▸ | ERBB2 | P04626 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12399074 | 0.91 | EGFR (0.49) | AURKABTKFGFR1KDRJAK3 | |
| SCHEMBL12371127 | 0.86 | FGFR1 (0.57) | BTKFGFR1KDRJAK3JAK2 | |
| SCHEMBL12635459 | 0.79 | ERBB2 (0.42) | AURKABTKFGFR1KDRJAK3 | |
| SCHEMBL12371121 | 0.77 | FGFR1 (0.67) | BTKFGFR1KDRJAK3JAK2 | |
| SCHEMBL12398988 | 0.77 | FGFR1 (0.55) | BTKFGFR1KDRJAK3JAK2 | |
| SCHEMBL12371102 | 0.76 | EGFR (0.60) | BTKJAK3JAK2EGFRSRC | |
| SCHEMBL12371145 | 0.73 | EGFR (0.47) | AURKABTKJAK3JAK2EGFR | |
| SCHEMBL19820324 | 0.72 | JAK3 (0.47) | BTKFGFR1KDRJAK3JAK2 | |
| SCHEMBL12398947 | 0.72 | CTSC (0.59) | BTKJAK3JAK2EGFR | |
| SCHEMBL2267020 | 0.71 | JAK3 (0.65) | BTKFGFR1KDRJAK3JAK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9879028-B2 | Compounds that modulate EGFR activity and methods for treating or preventing conditions therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2018-01-30 | — | — | US | disclosed |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | Gatekeeper Pharmaceuticals, Inc. (US) | 2014-01-09 | — | — | US | disclosed |
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | Gatekeeper Pharmaceuticals, Inc. | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207736-A1 | COMPOUNDS THAT MODULATE EGFR ACTIVITY AND METHODS FOR TREATING OR PREVENTING CONDITIONS THEREWITH | EGFR, ERBB2, BRCA1 | AURKA 2973/4885BTK 147/4885FGFR1 69/4885 |
| US-20140011810-A1 | Compounds that Modulate EGFR Activity and Methods for Treating or Preventing Conditions Therewith | EGFR, ERBB2, BRCA1 | AURKA 2973/4885BTK 147/4885FGFR1 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.